Maturitas
Volume 56, Issue 2 , Pages 111-112 , 20 February 2007

Why is the RUTH trial so important?

  • Amos Pines

      Affiliations

    • Corresponding Author InformationCorresponding author at: Department of Medicine “T”, Ichilov Hospital, 6 Weizman Street, Tel-Aviv 64239, Israel. Fax: +972 3 6962715.
    • ,
  • Yoram Levo

Received 25 September 2006 ,Accepted 28 September 2006.

References 

  1. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137
  2. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  3. U.S. Preventive Services Task Force . Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142:855–860
  4. EMEA public statement on recent publications regarding hormone replacement therapy. EMEA document 33065/03. 3 December; 2003.
  5. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605–619

PII: S0378-5122(06)00337-9

doi: 10.1016/j.maturitas.2006.09.008

Maturitas
Volume 56, Issue 2 , Pages 111-112 , 20 February 2007

Article Tools